Investigator Raphael Merriman, MD

Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)

Investigators: Edward Holt MD, Raphael Merriman MD, Kidist Yimam MD

Status: Active, Recruiting

Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV (LIMT-2)

Investigators: Stewart Cooper M.D., Raphael Merriman MD, Kidist Yimam MD

Status: Active, Recruiting

Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC) (ELATIVE)

Investigators: Edward Holt MD, Raphael Merriman MD, Kidist Yimam MD

Status: Active, Recruiting

Terlipressin for HRS-AKI in Liver Transplant Candidates (INFUSE)

Investigators: Todd Frederick M.D., Edward Holt MD, Raphael Merriman MD

Status: Active, Not Recruiting

A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC) (VIST

Investigators: Edward Holt MD, Raphael Merriman MD, Kidist Yimam MD

Status: Active, Recruiting

A Phase 3 Study Evaluating Long-term Efficacy and Safety of Lanifibranor in Adult Patients With (NASH) and Fibrosis 2 (F2)/Fibrosis 3 (F3) Stage of Liver Fibros

Investigator: Raphael Merriman MD

Status: Active, Recruiting

RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA

Investigators: Edward Holt MD, Raphael Merriman MD, Kidist Yimam MD

Status: Active, Recruiting